By David Russell, reporter at OptionMonsterNEW YORK -- Nektar Therapeutics ( NKTR - Get Report) has been trending higher, and traders cleaned up in the name Thursday. OptionMonster's tracking systems detected a spike of buying in the September 12 calls late in the morning, mostly for $1.25 and $1.35. These long calls locked in the price where shares can be purchased in the drug developer, giving them potentially explosive leverage in a rally. That's exactly what happened Thursday. Nektar's stock was up some 5% when the option trades hit, then climbed 13% to close the session at $12.69. The calls, by contrast, shot up more than 75% to $2.40. The stock has been swinging widely since late 2011 while making steadily higher lows. Thursday's bounce occurred around the same $11.10 level where it peaked in March and April, which could make some chart watchers think that it's in a bullish uptrend. Volume approached 9,500 at the strike. Previous open interest was just 473 contracts, indicating that new capital was put to work. Overall calls in the name outnumbered puts by an extremely bullish 52-to-1 ratio. Total option volume was 12 times greater than average. Russell has no positions in NKTR.
More from Options
Economist Perspective: Measuring and Managing Event Risk
The trade war poses as an event risk with conflicting binary outcomes. How can traders measure this type of event risk?
4 Key Lessons Crude Oil Traders Should Learn From This Week
Recent events in the Middle East and the oil market's reaction dramatically changes the landscape.
Funko Slides, Sadly, but Now Presents an Options Opportunity
Investors are punishing the seller of pop culture products because of a stock offering by two huge shareholders, which is creating an options play.